Jared Holz

Thanks so much for having me.

Appreciate it.

You've got one company growing very meaningfully in Eli Lilly and really seeming to not be losing any momentum.

If anything, the business is getting stronger.

And on the other hand, you've got Novo Nordisk that, for so many reasons, is seeing revenue degradation already in just the third year where these obesity treatments have been on the market and FDA approved.

So I think they're just going down two

And I think the biggest piece that I can really identify is that on the injectable side, which is obviously the lion's share of this market until the orals really get going, is only about 30% to 40%, depending on the day, right?

So already they're seeing their market share slip to about a third of the market.

And then I think the unfortunate thing for them is that they've got two things going on.

One, they've got this conversion to the oral therapy, which is very significant in terms of volume.

but at a fraction of the price right the introductory price for this market is only about 150 a month that's down from you know three four five hundred um and then the second thing is that semi-glutide is already on the ira list so they're seeing price degradation and they're seeing market share challenges both are going on simultaneously i mean it's just a recipe for a very challenging near term um you know the hope here is that you know the pipeline and and some of the things that they're doing strategically will will get them

to a better place, but it's going to take a while.

Yeah, I mean, I think they're excited for sure.

I mean, it's going extremely well.

I mean, I think the company has already put 200,000 people on this oral pill and it just came out at the beginning of the year.

So after four weeks or so, you've got almost a quarter of a million people that have either tried it or are on it.

That's pretty amazing.

Again, a lot of these patients are cash pay.

We don't know how long they're going to stay on the medication for.

They're working on higher doses or stronger doses to increase the weight loss.